Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

NEXT STORY
Dr. Jack Geltosky Elected to Medicenna Board of Directors
PREV STORY
GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

electroCore, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

BASKING RIDGE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today ...

author_avatar
NASDAQ Market News

Apricus Biosciences Completes Enrollment in Phase 2b Clinical Trial for Fispemifene in Men with Symptomatic Secondary Hypogonadism

SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

author_avatar
NASDAQ Market News

Aptose to Participate in Upcoming Investor Conferences

SAN DIEGO and TORONTO, March 02, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) ...

author_avatar
NASDAQ Market News